Stocksigma LogoStocksigma Logo

Mankind Pharma Targets Chronic Shift, BSV Scale-Up, and CAR-T Biopharma Entry

Mankind Pharma reported FY26 revenue of ₹14,278 Cr, posting an 18.1% CAGR over FY21–26. As of Q2 FY27, volume growth reached 6.2% versus IPM's 5.2%

Mankind Pharma Targets Chronic Shift, BSV Scale-Up, and CAR-T Biopharma Entry

Mankind Pharma Ltd · Investor Presentation · 27 Oct 2026, 10:44 pm

Mankind Pharma Targets Chronic Shift, BSV Scale-Up, and CAR-T Biopharma Entry Mankind Pharma reported FY26 revenue of ₹14,278 Cr, posting an 18.1% CAGR over FY21–26. As of Q2 FY27, volume growth reached 6.2% versus IPM's 5.2%. The company aims to expand its chronic portfolio from ~39% to ~50% of sales by FY30E and scale hospital sales to ~5%. Outstanding debt fell ~75% from peak levels to ~₹2,500 Cr, with full repayment targeted by 2028. Additionally, Mankind acquired a 70% stake in Belgium-based Armed Cell Therapeutics for €48 Mn to advance in-vivo CAR-T oncology candidates.

Original exchange filing (PDF)

More announcements from Mankind Pharma Ltd

All Mankind Pharma Ltd announcements